Adipocyte: A potential target for the treatment of atherosclerosis

Medical Hypotheses

Volumn 67, Issue 1, 2006, Pages 82-86

  Wu, Zhi hong ^a   Zhao, Shui ping ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPOCYTOKINE; ADIPONECTIN; APOLIPOPROTEIN E; ATORVASTATIN; BEZAFIBRATE; CERIVASTATIN; FENOFIBRATE; FIBRIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERLEUKIN 6; LEPTIN; MONOCYTE CHEMOTACTIC PROTEIN 1; OXIDIZED LOW DENSITY LIPOPROTEIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA AGONIST; TUMOR NECROSIS FACTOR ALPHA;

ACUTE CORONARY SYNDROME; ADIPOCYTE; ARTERY CALCIFICATION; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; BODY MASS; BODY WEIGHT; CELL FUNCTION; CELL PROLIFERATION; CLINICAL TRIAL; CYTOKINE PRODUCTION; DRUG EFFECT; DRUG MECHANISM; HEART INFARCTION; HUMAN; HYPERCHOLESTEROLEMIA; INFLAMMATION; ISCHEMIC HEART DISEASE; LIPID METABOLISM; MACROPHAGE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PHAGOCYTE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN SECRETION; PROTEIN TRANSPORT; SMOOTH MUSCLE FIBER; TARGET CELL; THROMBOCYTE AGGREGATION; THROMBOSIS;

ADIPOCYTES; ADIPOSE TISSUE; ANIMALS; ATHEROSCLEROSIS; CARDIOTONIC AGENTS; HUMANS; LEPTIN; LIPOPROTEINS, LDL; MODELS, BIOLOGICAL; RECEPTORS, OXIDIZED LDL;

EID: 33646111447     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mehy.2005.12.042     Document Type: Article

References (48)

1. Rashid M.N., Fuentes F., Touchon R.C., et al. Obesity and the risk for cardiovascular disease. Prev Cardiol 6 (2003) 42-47
2. Guerre-Millo M. Adipose tissue and adipokines: for better or worse. Diabetes Metab 30 (2004) 13-19
3. Dandona P., Weinstock R., Thusu K., et al. Tumor necrosis factor-alpha in sera of obese patients: fall with weight loss. J Clin Endocrinol Metab 83 (1998) 2907-2910
4. Ziccardi P., Nappo F., Giugliano G., et al. Reduction of inflammatory cytokine concentrations and improvement of endothelial functions in obese women after weight loss over 1 year. Circulation 105 (2002) 804-809
5. Itoh K., Imai K., Masuda T., et al. Relationship between changes in serum leptin levels and blood pressure after weight loss. Hypertens Res 25 (2002) 881-886
6. Folsom A.R., Qamhieh H.T., Wing R.R., et al. Impact of weight loss on plasminogen activator inhibitor (PAI-1), factor VII, and other hemostatic factors in moderately overweight adults. Arterioscler Thromb 13 (1993) 162-169
7. Nedvidkova J., Smitka K., Kopsky V., et al. Adiponectin, an adipocyte-derived protein. Physiol Res 54 (2005) 133-140
8. Yang W.S., Lee W.J., Funahashi T., et al. Weight reduction increases plasma levels of an adipose-derived anti-inflammatory protein, adiponectin. J Clin Endocrinol Metab 86 (2001) 3815-3819
9. Krause B.R., and Hartman A.D. Adipose tissue and cholesterol metabolism. J Lipid Res 25 (1984) 97-110
10. Kovanen P.T., Nikkila E.A., and Miettinen T.A. Regulation of cholesterol synthesis and storage in fat cells. J Lipid Res 16 (1975) 211-223
11. Zhao S.P., Wu J., Zhang D.Q., et al. Fenofibrate enhances CD36 mediated endocytic uptake and degradation of oxidized low density lipoprotein in adipocytes from hypercholesterolemia rabbit. Atherosclerosis 177 (2004) 255-262
12. Ren J. Leptin and hyperleptinemia - from friend to foe for cardiovascular function. J Endocrinol 181 (2004) 1-10
13. Sharma V., and McNeill J.H. The emerging roles of leptin and ghrelin in cardiovascular physiology and pathophysiology. Curr Vasc Pharmacol 3 (2005) 169-180
14. Kang S.M., Kwon H.M., Hong B.K., et al. Expression of leptin receptor (Ob-R) in human atherosclerotic lesions: potential role in intimal neovascularization. Yonsei Med J 41 (2000) 68-75
15. Hasty A.H., Shimano H., Osuga J., et al. Severe hypercholesterolemia, hypertriglyceridemia, and atherosclerosis in mice lacking both leptin and the low density lipoprotein receptor. J Biol Chem 276 (2001) 37402-37408
16. Bodary P.F., Westrick R.J., Wickenheiser K.J., et al. Effect of leptin on arterial thrombosis following vascular injury in mice. JAMA 287 (2002) 1706-1709
17. Wallace A.M., McMahon A.D., Packard C.J., et al. Plasma leptin and the risk of cardiovascular disease in the west of Scotland coronary prevention study (WOSCOPS). Circulation 104 (2001) 3052-3056
18. Ciccone M., Vettor R., Pannacciulli N., et al. Plasma leptin is independently associated with the intima-media thickness of the common carotid artery. Int J Obes Relat Metab Disord 25 (2001) 805-810
19. Reilly M.P., Iqbal N., Schutta M., et al. Plasma leptin levels are associated with coronary atherosclerosis in type 2 diabetes. J Clin Endocrinol Metab 89 (2004) 3872-3878
20. Kumada M., Kihara S., Sumitsuji S., et al. Association of hypoadiponectinemia with coronary artery disease in men. Arterioscler Thromb Vasc Biol 23 (2003) 85-89
21. Pischon T., Girman C.J., Hotamisligil G.S., et al. Plasma adiponectin levels and risk of myocardial infarction in men. JAMA 291 (2004) 1730-1737
22. Kubota N., Terauchi Y., Yamauchi T., et al. Disruption of adiponectin causes insulin resistance and neointimal formation. J Biol Chem 277 (2002) 25863-25866
23. Okamoto Y., Kihara S., Ouchi N., et al. Adiponectin reduces atherosclerosis in apolipoprotein E-deficient mice. Circulation 106 (2002) 2767-2770
24. Okamoto Y., Artia Y., Nishida M., et al. An adipocyte-derived plasma protein, adiponectin, adheres to injured vascular walls. Horm Metab Res 32 (2000) 47-50
25. Goldstein B.J., and Scalia R. Adiponectin: a novel adipokine linking adipocytes and vascular function. J Clin Endocrinol Metab 89 (2004) 2563-2568
26. Ouchi N., Kihara S., Funahashi T., et al. Obesity, adiponectin and vascular inflammatory disease. Curr Opin Lipidol 14 (2003) 561-566
27. Plutzky J. Inflammatory pathways in atherosclerosis and acute coronary syndromes. Am J Cardiol 88 (2001) 10K-15K
28. Ferroni P., Basili S., Falco A., et al. Inflammation, insulin resistance, and obesity. Curr Atheroscler Rep 6 (2004) 424-431
29. Nicoletti G., Giugliano G., Pontillo A., et al. Effect of a multidisciplinary program of weight reduction on endothelial functions in obese women. J Endocrinol Invest 26 (2003) RC5-RC8
30. Heilbronn L.K., Noakes M., and Clifton P.M. Energy restriction and weight loss on very-low-fat diets reduce C-reactive protein concentrations in obese, healthy women. Arterioscler Thromb Vasc Biol 21 (2001) 968-970
31. Giugliano G., Nicoletti G., Grella E., et al. Effect of liposuction on insulin resistance and vascular inflammatory markers in obese women. Br J Plast Surg 57 (2004) 190-194
32. Axelsson J., Heimburger O., Lindholm B., et al. Adipose tissue and its relation to inflammation: the role of adipokines. J Ren Nutr 15 (2005) 131-136
33. Yudkin J.S., Stehouwer C.D., Emeis J.J., et al. C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction: a potential role for cytokines originating from adipose tissue?. Arterioscler Thromb Vasc Biol 19 (1999) 972-978
34. Zhao S.P., and Zhang D.Q. Atorvastatin reduces interleukin-6 plasma concentration and adipocyte secretion of hypercholesterolemic rabbits. Clin Chim Acta 336 (2003) 103-108
35. Zhao S.P., and Wu J. Fenofibrate reduces tumor necrosis factor-alpha serum concentration and adipocyte secretion of hypercholesterolemic rabbits. Clin Chim Acta 347 (2004) 145-150
36. Ehara S., Ueda M., Naruko T., et al. Elevated levels of oxidized low density lipoprotein show a positive relationship with the severity of acute coronary syndromes. Circulation 103 (2001) 1955-1960
37. Meisinger C., Baumert J., Khuseyinova N., et al. Plasma oxidized low-density lipoprotein, a strong predictor for acute coronary heart disease events in apparently healthy, middle-aged men from the general population. Circulation 112 (2005) 651-657
38. Porreca E., Di Febbo C., Moretta V., et al. Circulating leptin is associated with oxidized LDL in postmenopausal women. Atherosclerosis 175 1 (2004) 139-143
39. Vasankari T., Fogelholm M., Kukkonen-Harjula K., et al. Reduced oxidized low-density lipoprotein after weight reduction in obese premenopausal women. Int J Obes Relat Metab Disord 25 (2001) 205-211
40. van Harmelen V., Skurk T., Rohrig K., et al. HMG-CoA reductase inhibitor cerivastatin inhibits interleukin-6 expression and secretion in human adipocytes. Horm Metab Res 35 (2003) 466-470
41. Zhao S.P., Wu Z.H., Wu J., et al. Effect of atorvastatin on tumor necrosis factor alpha serum concentration and mRNA expression of adipose in hypercholesterolemic rabbits. J Cardiovasc Pharmacol 46 (2005) 185-189
42. Zhao S.P., and Wu Z.H. Atorvastatin reduces serum leptin concentration in hypercholesterolemic rabbits. Clin Chim Acta 360 (2005) 133-140
43. Koh K.K., Quon M.J., Han S.H., et al. Additive beneficial effects of losartan combined with simvastatin in the treatment of hypercholesterolemic, hypertensive patients. Circulation 110 (2004) 3687-3692
44. Zhao S.P., and Zhang D.Q. Atorvastatin enhances cellular uptake of oxidized LDL in adipocytes from hypercholesterolemic rabbits. Clinnica Chimica Acta 339 (2004) 189-194
45. Cabrero A., Alegret M., Sanchez R.M., Adzet T., Laguna J.C., and Vazquez M. Bezafibrate reduces mRNA levels of adipocyte markers and increases fatty acid oxidation in primary culture of adipocytes. Diabetes 50 (2001) 1883-1890
46. Shirai Y., Yaku S., and Suzuki M. Metabolic regulation of leptin production in adipocytes: a role of fatty acid synthesis intermediates. J Nutr Biochem 15 (2004) 651-656
47. Mori Y., Oana F., Matsuzawa A., Akahane S., and Tajima N. Short-term effect of bezafibrate on the expression of adiponectin mRNA in the adipose tissues: a study in spontaneously type 2 diabetic rats with visceral obesity. Endocrine 25 (2004) 247-251
48. Koh K.K., Quon M.J., Han S.H., et al. Additive beneficial effects of fenofibrate combined with atorvastatin in the treatment of combined hyperlipidemia. J Am Coll Cardiol 45 (2005) 1649-1653